Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness

Publication date: Available online 12 October 2017 Source:Respiratory Physiology & Neurobiology Author(s): Capucine Morélot-Panzini, Carl R. O’Donnell, Robert W. Lansing, Richard M. Schwartzstein, Robert B. Banzett Aerosolized furosemide has been shown to relieve dyspnea; nevertheless, all published studies have shown great variability in response. This dyspnea relief is thought to result from the stimulation of slowly adapting pulmonary stretch receptors simulating larger tidal volume. We hypothesized that better control over aerosol administration would produce more consistent dyspnea relief; we used a clinical ventilator to control inspiratory flow and tidal volume. Twelve healthy volunteers inhaled furosemide (40mg) or placebo in a double blind, randomized, crossover study. Breathing Discomfort was induced by hypercapnia during constrained ventilation before and after treatment. Both treatments reduced breathing discomfort by 20% full scale. Effectiveness of aerosol furosemide treatment was weakly correlated with larger tidal volume. Response to inhaled furosemide was inversely correlated to furosemide blood level, suggesting that variation among subjects in the fate of deposited drug may determine effectiveness. We conclude that control of aerosol delivery conditions does not improve consistency of treatment effect; we cannot, however, rule out placebo effect.

Source: Respiratory Physiology and Neurobiology - October 12, 2017 Category: Respiratory Medicine Source Type: research